According to a document released by all five authorities, by 2030, intelligent diagnosis and treatment assistance will be universal in basic terms across China's primary-level medical institutions, including community and village clinics. Meanwhile, hospitals at or above the second grade in China's three-tier hospital system will widely adopt AI technologies such as intelligent medical-imaging diagnosis and clinical decision-making support technologies.

According to the results of the basic research, different medical institutions have selected different imported and domestic brand instruments: 38 domestic and 58 imported.

Grail has raised $300 million in a Series C financing round that wasoversubscribed, according to the firm.Ally Bridge Group led the round alongwith Hillhouse Capital Group and 6 Dimensions Capital. Blue Pool Capital, ChinaMerchant Securitie

Freenome has initiated a clinical study tohelp bring an AI-Genomics blood test for colorectal cancer to the U.S. market. Freenome is looking to build a diagnostictest that can learn from its mistakes. The South San Francisco, CA- basedcompa